The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | The limitations of HMAs in MDS: unmet needs in higher-risk disease
In this video, Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, briefly discusses the limitations of hypomethylating agents (HMAs) in myelodysplastic syndromes (MDS), stating that only 30-40% of patients achieve disease remission, with clinical benefit lasting around one year. Dr Della Porta highlights the significant unmet need for patients with high-risk disease, particularly those not eligible for allogeneic stem cell transplantation. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
